The ubiquitin system regulates essential cellular processes in eukaryotes. Ubiquitin is ligated to substrate proteins as monomers or chains and the topology of ubiquitin modifications regulates substrate interactions with specific proteins. Thus ubiquitination directs a variety of substrate fates including proteasomal degradation 1 . Deubiquitinase enzymes cleave ubiquitin from substrates and are implicated in disease 2 ; for example, ubiquitinspecific protease-7 (USP7) regulates stability of the p53 tumour suppressor and other proteins critical for tumour cell survival 3 . However, developing selective deubiquitinase inhibitors has been challenging 4 and no co-crystal structures have been solved with small-molecule inhibitors. Here, using nuclear magnetic resonance-based screening and structure-based design, we describe the development of selective USP7 inhibitors GNE-6640 and GNE-6776. These compounds induce tumour cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, including PIM kinase inhibitors. Structural studies reveal that GNE-6640 and GNE-6776 non-covalently target USP7 12 Å distant from the catalytic cysteine. The compounds attenuate ubiquitin binding and thus inhibit USP7 deubiquitinase activity. GNE-6640 and GNE-6776 interact with acidic residues that mediate hydrogen-bond interactions with the ubiquitin Lys48 side chain 5 , suggesting that USP7 preferentially interacts with and cleaves ubiquitin moieties that have free Lys48 side chains. We investigated this idea by engineering di-ubiquitin chains containing differential proximal and distal isotopic labels and measuring USP7 binding by nuclear magnetic resonance. This preferential binding protracted the depolymerization kinetics of Lys48-linked ubiquitin chains relative to Lys63-linked chains. In summary, engineering compounds that inhibit USP7 activity by attenuating ubiquitin binding suggests opportunities for developing other deubiquitinase inhibitors and may be a strategy more broadly applicable to inhibiting proteins that require ubiquitin binding for full functional activity.
; for example, ubiquitinspecific protease-7 (USP7) regulates stability of the p53 tumour suppressor and other proteins critical for tumour cell survival 3 . However, developing selective deubiquitinase inhibitors has been challenging 4 and no co-crystal structures have been solved with small-molecule inhibitors. Here, using nuclear magnetic resonance-based screening and structure-based design, we describe the development of selective USP7 inhibitors GNE-6640 and GNE-6776. These compounds induce tumour cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, including PIM kinase inhibitors. Structural studies reveal that GNE-6640 and GNE-6776 non-covalently target USP7 12 Å distant from the catalytic cysteine. The compounds attenuate ubiquitin binding and thus inhibit USP7 deubiquitinase activity. GNE-6640 and GNE-6776 interact with acidic residues that mediate hydrogen-bond interactions with the ubiquitin Lys48 side chain 5 , suggesting that USP7 preferentially interacts with and cleaves ubiquitin moieties that have free Lys48 side chains. We investigated this idea by engineering di-ubiquitin chains containing differential proximal and distal isotopic labels and measuring USP7 binding by nuclear magnetic resonance. This preferential binding protracted the depolymerization kinetics of Lys48-linked ubiquitin chains relative to Lys63-linked chains. In summary, engineering compounds that inhibit USP7 activity by attenuating ubiquitin binding suggests opportunities for developing other deubiquitinase inhibitors and may be a strategy more broadly applicable to inhibiting proteins that require ubiquitin binding for full functional activity.
USP7 is a genetically validated deubiquitinase for MDM2, a ubi quitin ligase that promotes degradation of the tumour suppressor p53. USP7 depletion enhances ubiquitination of USP7 substrates, including MDM2. Subsequent MDM2 proteasomal degradation stabilizes p53, thus promoting cell cycle arrest and apoptosis 3, 6, 7 . USP7 inhibition enhances ubiquitination of additional substrates that also regulate cellular physiology (Fig. 1a) 3, [7] [8] [9] [10] [11] . To identify USP7 inhibitors, we esta blished an activitybased highthroughput screening cascade (Extended Data Fig. 1a ). In parallel we developed a nuclear magnetic resonance (NMR) screen to identify USP7 catalytic domainbinding fragments (Extended Data Fig. 1b) . A hittolead selection cascade was established to guide optimization of highthroughput screening and NMR hits into more potent USP7 inhibitors. Selectivity assays and structural biology directed medicinal chemistry design at the apex of the cascade. Assays to measure total and ubiquitinatedMDM2 levels were implemented as proximal indicators of USP7 activity, followed by viability assays using inactive compounds from matched chemical series as negative controls (Fig. 1b) .
Progression of highthroughput screening and NMR screen hits through the hittolead selection cascade identified a series of fragments having favourable properties . Optimization of the parent fragment GNE2916 yielded GNE6640 and GNE6776 (Extended Data Fig. 3a ). These USP7 inhibitors enhanced endogenous MDM2 ubiquitination while achieving selectivity over USP47 (which has high USP7homology) and USP5, a highly active deubiquitinase 12 . Both compounds accelerated endogenous MDM2 turnover with cycloheximide, a necessary co treatment as MDM2 is a p53 target gene (Fig. 1a, c and Extended Data Fig. 3b ). Accordingly, both GNE6640 and GNE6776, but not controls GNE2118 and GNE6641, promoted endogenous MDM2 ubiquitination with Lys48 (K48)linked polyubiquitin chains, which direct proteasomal degradation 13 (Fig. 1d and Extended Data Fig. 3c ). Active USP7 inhibitors stabilized p53 and upregulated p21 in wildtype cells, but not in p53null or USP7null cells ( Fig. 1e and Extended Data Fig. 3b ). These data were corroborated by significantly decreased viability of wildtype, but not USP7 null cells, treated with active inhibitors (Extended Data Fig. 3d , e). Thus GNE6640 and GNE6776 target cellular USP7, MDM2, and p53 signalling pathways.
Previously reported deubiquitinase inhibitors are neither potent nor selective when evaluated in a massspectrometrybased activity assay 4 . In this assay, GNE6640 and GNE6776 selectively inhibited recombi nant USP7 relative to 36 other deubiquitinases (Fig. 2a and Extended Data Fig. 4a ). GNE6776 remained selective even at 100 μ M, a more than sixfold higher concentration than used in cellular assays (Fig. 2a and Extended Data Fig. 4b ). Because deubiquitinases are regulated by numerous cellular mechanisms 14 , we developed an activitybased probe assay to evaluate effects on endogenous deubiquitinases (J.H. et al., manuscript in preparation) . GNE6640 or GNE6776 signifi cantly inhibited USP7 while remaining selective against 44-47 other detected deubiquitinases (Fig. 2b and Extended Data Fig. 4c, d) . Given the favourable features of these inhibitors, we investigated their efficacy in animal models. Pharmacodynamic and pharmacokinetic studies indicated that GNE6776 is orally bioavailable and promotes ontarget pathway modulation in human xenografts (Extended Data Fig. 4e-i) . Although efficacious exposure was only transiently achieved, GNE6776 caused modest, although significant, EOL1 xenograft growth delay (Extended Data Fig. 4j ). Developing USP7 inhibitors that have improved druglike properties will be necessary to comprehen sively evaluate USP7 inhibition in vivo.
USP7 and MDM2 regulate proteins other than p53 (refs 3, 7-11, 15) (Fig. 1a) . Having confirmed the selectivity and cellular activity of GNE 6640 and GNE6776, we prescreened 441 cell lines in 3day viability assays to enable an unbiased analysis of cellular factors that regulate USP7 inhibitor sensitivity (Extended Data Fig. 5a ). GNE6641 was inactive in all cell lines whereas GNE6640 decreased viability of 108 cell lines with halfmaximal inhibitory concentration (IC 50 ) ≤ 10 μ M (data not shown). Next, we selected a subset of 181 cell lines displaying a range of sensitivities for additional analysis. GNE6641 remained inactive in 5day viability assays, whereas GNE6640 and GNE6776 decreased viability of 54 and 6 cell lines, respectively, with IC 50 ≤ 10 μ M (Extended Data Fig. 5b and Supplementary Table 1 ). Viability data and exome sequencing analysis were integrated to identify features associated with compound sensitivity. Acute myeloid leukaemia (AML) cell lines had increased sensitivity to GNE6640 (Extended Data Fig. 5c , e). Loss offunctionmutant TP53 lines were, in general, less responsive than wildtype TP53 lines, but the trend was not significant (Extended Data Fig. 5d ). Indeed, the TP53 R175 hotspot was associated with increased sensitivity, whereas the Y220 hotspot was associated with decreased sen sitivity (Extended Data Fig. 5c , e and Supplementary Table 1). Although both compounds decreased proliferation and activated caspases in TP53 wildtype cell lines, these effects were reduced, but not abolished, in TP53null cell lines (Extended Data Fig. 6a-c ). Combining GNE6640 with doxorubicin or cisplatin, DNAdamaging agents that activate the p53 response 16 , enhanced USP7 inhibitor efficacy (Extended Data Fig. 6d , e). Thus the MDM2 or p53 pathway is a mediator of GNE6640 and GNE6776 cellular activity but is not the only determinant. These findings corroborate genetic studies that have crossed TP53 −/− and USP7 −/− mice, which minimally rescues USP7 −/− embryonic lethality 7 . The enhanced efficacy of GNE6640 in combination with DNA damaging agents suggested a strategy to identify signalling pathways that intersect with USP7 inhibition. We therefore screened EOL1 AML cells with GNE6640 or GNE6776 in combination with 589 chemo therapeutic or targeted agents. Top hits included PI3K and PIM kinase inhibitors (Extended Data Fig. 6f, g and Supplementary Table 2) . PIM kinases share substrates with PI3K pathway kinases including TSC1/2 and Bad (Extended Data Fig. 7a ) 17 . Given the role of PIM2 in hae matological malignancies 17 , we confirmed combination efficacy with Bliss analysis using PIM inhibitors GDC0339 (ref. 18) or GDC0570 . Both inhibitors share struc tural similarities and are selectively potent against PIM kinases (X. W. et al., manuscripts in preparation) . In mechanistic studies, GNE6776 promoted a modest elevation of p21 levels in AML cell lines whereas PIM2 levels were reduced. The GNE6776induced decrease in PIM2 levels was rescued by inhibition of the ubiquitinactivating enzyme UAE1 or the proteasome inhibitor bortezomib 13 . PIM2 levels were lower in USP7null cells, which was rescued by proteasome inhibition, collectively indicating that USP7 stabilizes PIM2 levels via a ubiquitin and proteasomedependent mechanism (Extended Data Fig. 7e, f) . A treatment time course with GNE6776, GDC0570 or both compounds revealed that, as previously reported 17 , GDC0570 reduced phospho rylation of Bad and S6 and decreased expression of shortlived proteins p21 and Mcl1. GNE6776 decreased PIM2 levels and, remarkably, also reduced S6 and Bad phosphorylation and total Mcl1 levels, similar to PIM inhibition. In combination, GNE6776 and GDC0570 treat ments enhanced cleavage of poly(ADPribose) polymerase (PARP) and caspase3, mechanistically confirming the cell viability studies (Fig. 2d) . We therefore hypothesized that PIM2 is a USP7 substrate. In support of this idea, endogenous USP7 and PIM2 coimmunoprecipitated and GNE6776 treatment enhanced PIM2 ubiquitination ( Fig. 2e and Extended Data Fig. 7g ). Recombinant USP7, but not the C223S 
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G N E catalytic mutant, deubiquitinated PIM2 in vitro (Extended Data Fig. 7h ). Simultaneous PIM kinase inhibition and USP7 inhibitor mediated protein degradation thus antagonize PIM activity and cell viability more than does either treatment individually. These data reveal crosstalk between USP7 and PIM signalling and expand the repertoire of USP7regulated oncogenic pathways.
Given the selectivity and efficacy of GNE6640 and GNE 6776, understanding the molecular mechanisms by which these Fig. 8a ). NMR analysis confirmed that USP7 inhibitors weaken USP7 catalytic domain interactions with native ubiquitin (Fig. 3a and Extended Data Fig. 8b, c) . Analysis of cocrystal structures revealed that both compounds bind into a pocket approximately 12 Å from the catalytic triad that is located at the interface of the USP7 catalytic domain palm, fingers, and thumb subdomains ( Fig. 3b and Extended Data Fig. 8d, e) . The phenol rings of the phenolaminopyridine moieties are buried in the pocket and the hydroxyl groups are engaged in hydrogenbond interactions with USP7H403. The 2aminopyridine is directed out of the pocket towards solvent with the 2amino group engaging USP7D349 (Extended Data Fig. 8d) . The substituents at the 5position of the aminopyridine-the pyridinecarboxamide (GNE6776) and indazole (GNE6640)-are largely solventexposed and lie between the α 5 and α 6 helices. The NH atoms of the GNE6776 carboxamide moiety engage USP7D305 on the α 5 helix, whereas the indazole of GNE6640 makes extensive van der Waals contacts in the crevice between α 5 and α 6 (Fig. 3c and Extended Data Fig. 8d) . Comparison of the cocrystal structures of GNE6776 and GNE6640 with the USP7-ubiquitin complex (Protein Data Bank (PDB) accession number 1NBF) reveals that the compounds sterically inhibit ubiquitin binding and prevent transition of the USP7 catalytic domain α 5 helix to the active conformation 5 ( Fig. 3c and Extended Data Fig. 8d ). However, given the extensive interactions between USP7 catalytic domain and ubiquitin
5
, we investigated the importance of the USP7 residues that interact with the ubiquitinK48 side chain. The ubiquitin K48A mutant has reduced affinity for USP7 catalytic domain (Extended Data  Fig. 9a) ; similarly, recombinant D305A/E308A USP7 catalytic domain failed to cleave tetraK48 or tetraK63linked polyubiquitin conju gated to a TAMRAlabelled peptide 19 . This apparent inactivity was due to a significant increase in K m (ref. 20) (Extended Data Fig. 9b, c) . Expression of a D305A/E308A USP7fulllength mutant increased K48linked polyubiquitination on endogenous MDM2, comparable to expression of catalytically inactive USP7 (Extended Data Fig. 9d ). Thus ubiquitinK48 and USP7D305/E308 residues are critical for USP7-ubiquitin binding and substrate deubiquitination.
The GNE6640 and GNE6776 binding modes suggested that USP7 may preferentially associate with ubiquitin moieties that have free K48 side chains. Mechanistically, this could direct USP7 to dis tal subunits of K48linked polyubiquitin, resulting in sequential dis taltoproximal chain depolymerization (exocleavage). However, in nonK48linked chains, USP7 may bind and cleave proximally to any ubiquitin moieties having accessible K48 side chains (exo, endo, or Data Fig. 10a ). To evaluate this idea, we engi neered K48 and K63linked diubiquitin with differentially labelled distal and proximalubiquitin subunits using spectroscopically dis tinct amino acids. To select ubiquitin residues for isotopic labelling, we evaluated chemical shift perturbations induced by USP7 binding (Extended Data Fig. 10b ). The cluster of residues L8, T12, T14, and L15 broaden upon USP7 catalytic domain binding and are well resolved in the spectra; thus Leu residues were 15 Nlabelled in the proximal diubiquitin and Thr residues were 15 Nlabelled in the distal subunit ( Fig. 4a and Extended Data Fig. 10b, c) . NMR analysis showed preferen tial USP7 catalytic domain binding to the distal subunit of K48linked diubiquitin, whereas USP7 catalytic domain binding was similar to both proximal and distal K63linked di ubiquitin subunits ( Fig. 4a and Extended Data Fig. 10c ). Importantly, both D305A USP7 and D305A/ E308A USP7 catalytic domain mutants demonstrated similar binding to both proximal and distal K48linked diubiquitin subunits (Fig. 4a) . On the basis of these data, we evaluated whether differential di ubiquitin binding affects the dynamics of ubiquitin chain depolyme rization by USP7. A previous study reported that USP7 cleaves K6, K11, K33, K48, and K63linked diubiquitins with similar k cat and K m values, indicating that different isopeptide bond conformations do not substantially impact cleavage efficiency 20 . Remarkably, our studies reveal that USP7 sequentially depolymerizes tetraK48linked ubiqui tin from the distal residue (exocleavage) whereas tetraK63ubiquitin chains are cleaved via a combination of exo, endo, or basecleavage, as nearly complete depolymerization occurs within 4 min ( Fig. 4b and Extended Data Fig. 10d, e) . Thus USP7 preferentially binds ubiquitin moieties that have free K48 side chains, resulting in protracted and sequential depolymerization of K48linked polyubiquitin.
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Herein we describe GNE6640 and GNE6776, selective USP7 inhibitors that possess a structurally defined mechanism of inhibi tion. Establishing stringent screening cascades was critical for selecting and optimizing ontarget inhibitors. Combination studies revealed a previously undescribed intersection between USP7 deubiquitinase activity and PIM kinases in regulating cell viability. Cocrystal struc tures of GNE6640 or GNE6776 pointed to the importance of the complementary charged interactions between USP7D305/E308 and ubiquitinK48 side chains, which we confirmed using mutational analysis. Notably, D305G has been identified as a somatic lossof function mutant in patients with acute lymphoblastic leukaemia 21 . NMR analysis of USP7 binding to native monoubiquitin and differ entially labelled diubiquitins revealed that USP7 preferentially inter acts with ubiquitin moieties having free K48 side chains. It has been proposed that the inefficiency of some deubiquitinases to depolymerize longer substrateconjugated K48linked chains enables a threshold for proteasometargeting polyubiquitination
22
; our studies substantiate this idea and provide a biophysical mechanism. Numerous proteins, includ ing other deubiquitinases, ubiquitin ligases, DNA repair and endocyto sis machinery, and epigenetic regulators are functionally dependent on ubiquitin binding 23 . Developing selective inhibitors that attenuate ubiq uitin binding is an effective strategy for USP7 inhibition. Our studies demonstrate the feasibility of this approach, which may have broader applications for inhibiting other classes of ubiquitinbinding proteins.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. The peptide is tagged with glutathione Stransferase (GST) on the N terminus and with eight histidine residues on the C terminus (GST-UbA10His). The tags are detected by antiGSHd2 (TRFRET acceptor) and antiHis europium (TRFRET donor), respectively. Cleavage of this substrate by USP7 at the ubiquitin C terminus results in separation of these two tags and loss of TRFRET signal. Compounds were dispensed into 1,536well black plates (MaKO, Aurora Microplates) followed by 2 μ l fulllength recombinant USP7 in assay buffer (50 mM HEPES pH 7.5, 0.1% Prionex (Pentapharm), 0.01% Triton X100, and 10 mM dithiothreitol (DTT)). After a 10min incubation, the reaction was started by the addition of 2 μ l GST-UbA10His substrate in assay buffer. After 75 min of reaction, 2 μ l of a detection antibody reagent, containing antiHiseuropium (Life Technologies) and antiGSTd2 (CISbio) in assay buffer were added. After 60 min, the fluorescence at 618 nm and 671 nm with excitation at 340 nm was read on a ViewLux reader (PerkinElmer). Cleavage of the doubly tagged substrate resulted in loss of TRFRET signal, whereas inhibition of USP7 by compound restored the signal. The TRFRET ratio was calculated as fluorescence at 671 nm divided by fluorescence at 618 nm. TRFRET ratios were normalized to controls to determine the percentage inhibition for the single concentration screen. For confirmation in concentration-response mode (ten points with n = 2), percentage inhibition was plotted against compound concentration, and the data were fitted to a four parameter curve with Screener Assay Analyzer (Genedata) to determine IC 50 values. The assay buffer was optimized to maintain enzyme stability and to maximize assay signal to background: Triton X100 was included to prevent nonspecific adsorption of the enzyme and/or substrate to the assay plate and/or to compound aggregates, Prionex carrier protein was included to help stabilize the enzyme and to prevent nonspecific adsorption to container and tubing surfaces as well as to minimize nonspecific inhibition by library compounds, and DTT served to maintain good USP7 activity and minimize the impact of inhibitors that act through redox cycling. Reagent concentrations were optimized for good assay performance at approximately 50% substrate conversion in the signal decrease assay with a key aim of minimizing the required concentration of USP7. The GSTUbA10His concentration was adjusted to maximize assay signal, antiGSTd2 concentration was adjusted approximately in parallel with that of the substrate, and antiHiseuropium was used at a concentration that represented a minimum that was compatible with robust detection on the ViewLux plate reader. Timecourse evaluations were conducted to confirm that the enzyme concentration (10 nM) and reaction time (75 min) were in the linear range of enzyme activity. Additionally, extended time courses for the detection reaction were used to demonstrate that the 60min incubation was sufficient to reach equilibrium. Under the final assay conditions, reagent stability studies indicated greater than 20 h of acceptable performance. Over the course of the screen, Z′ values averaged 0.76. USP7 di-ubiquitin FRET activity assay. Potential USP7 inhibitors were confirmed in an orthogonal activity assay with an internally quenched K63linked diubiquitin substrate (U310, Boston Biochem). Conditions were similar to those used for the UbA10 TRFRET activity assay. Compounds dispensed into 1,536well plates were preincubated with fulllength recombinant USP7 in assay buffer for 10 min, and the reaction was started by the addition of 2 μ l of the diubiquitin substrate. During the 60min incubation, cleavage of the substrate by USP7 resulted in the release of quenching of the TAMRA tag by the QXl tag and thus an increase in fluorescence. The fluorescence intensity was read with excitation at 540 nm and emission at 585 nm. Concentration-response assay methods and data analyses were conducted as for the UbA10 TRFRET assay. USP7 Ubiquitin/Rho110 activity assay. Potential USP7 inhibitors were also confirmed in an orthogonal activity assay with ubiquitin/rhodamine110 as substrate. Compounds were preincubated for 10 min with 2 μ l fulllength recom binant USP7 in assay buffer, and the reaction was started by the addition of 2 μ l of ubiquitin/rhodamine110 (U555, Boston Biochem). After a 60min reaction in which USP7 cleaved the rhodamine110 from the ubiquitin and thus increases fluorescence, the fluorescence intensity was read with excitation at 485 nm and emission at 535 nm. General assay conditions and data analyses were as described above. USP7 di-ubiquitin cleavage assay with mass spectrometric detection. To further validate compounds that met the initial highthroughput screen confirma tion criteria, the ability of compounds to inhibit diubiquitin cleavage was assessed by monitoring the conversion to ubiquitin by mass spectrometry. Compounds were dispensed into 384well polypropylene plates (Greiner BioOne), and 10 μ l USP7 were added and allowed to incubate for 10 min. The reaction was started by the addition of 10 μ l of K48linked diubiquitin substrate (UC200, Boston Biochem) and allowed to progress for 70 min; then it was stopped by the addition of 20 μ l 2% formic acid. The assay plates were stored frozen at − 80 °C until analysis by mass spectrometry at Agilent Technologies. Before quantification, the enzyme reaction was passed over a RapidFire cartridge to remove buffer components. Both di ubiquitin substrate consumption and ubiquitin product formation were monitored by mass spectrometry using multiple reaction monitoring (MRM) in positive ion mode with parent ion/daughter ion transitions of 1142.1/260.1 and 770.8/817.7, respectively. The percentage conversion of substrate was plotted as a function of compound concentration to generate the IC 50 values as indicated above. NMR screen and binding studies. All NMR spectra were recorded on Bruker Avance 600 MHz and 800 MHz spectrometers operating at 14.1 and 18.8 T using tripleresonance cryogenic probes optimized for proton detection. All two dimensional spectra were acquired with a spectral width of 16 p.p.m. and 2,048 (TROSY) or 954 (SOFAST) data points in the direct proton dimension and 28 p.p.m. and 192 sample points in the 15 N dimension with echo/antiecho (TROSY) or StatesTPPI (SOFAST) type selection. The resulting free induction decay resolution was 12.52 and 19.05 Hz per data point for the TROSY and 20.08 and 17.10 Hz per data point for the SOFAST spectra, respectively. All spectra were recorded at 300 K. The pH was adjusted to 7.2 without correction owing to isotope shifts. For data processing, NMRPipe/NMRDraw and the BRUKER software package TOPSPIN 3.2 were used. All data evaluation was done in NMR view and CCPN. Visualization and presentation of the threedimensional tertiary USP7 as well as related protein structures from the RSCB Protein Database were done in PyMOL (PyMOL Molecular Graphics System, version 1.7.4, Schrödinger). All samples contained 137 mM NaCl, 10 mM Na 2 HPO 4 , 27 mM KCl, and 1.8 mM KH 2 PO 4 adjusted to a pH of 7.2 and contained 7% (w/w) 2 H 2 O and 0.5 μ M NaN 3 . Ubiquitin titration experiments were done by addition of purified bovine ubiquitin (from erythro cytes, Sigma) from a stock solution of 20 mM in the same buffer. All proton chemical shifts were referenced to internal DSS (50 μ M) and 15 N referenced indirectly using the 1 H chemical shift of the methyl group in DSS by multiplication with a factor of 0.101329118. NMR screening conditions. The primary fragment screen was performed on 4,871 fragments in mixtures of 5. The individual compound concentration was 500 μ M and the concentration of unlabelled USP7 was 7 μ M. Binders were identified by the presence of signals stemming from the individual ligand in the proton satura tion transfer difference spectra recorded at 284 K. The criterion used to identify a binder was a signaltonoise ratio of above 5. All primary binders were re measured as a single compound to confirm binding. Confirmed binders were defined as compounds with a saturation transfer difference signaltonoise ratio of above 10. All confirmed binders were tested again at 2-2.5 mM, by proteinobserved Nlabelled USP7 in the absence and presence of USP7 inhibitors were fitted to the function for a twostate fast exchanging equilibrium based on concentrationdependent chemical shift perturbations: GNE-2118 , GNE-6776, GNE-6641, GNE-2931 , GNE-2917 , and GNE-2916 3,5Dibromo4ethylpyridin2amine: into a 500ml threenecked round bottom flask purged and maintained with an inert atmosphere of nitrogen were placed 4ethylpyridin2amine (10 g, 81.85 mM), tetrahydrofuran (200 ml), and NBS (29 g, 162.94 mmol) at 0 °C. The resulting solution was stirred at room temperature for 15 min and then concentrated under vacuum. The residue was purified on a silica gel column eluting with DCM/MeOH (100:1 to 20:1), to afford 18 g (79%) of the title compound.
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Compound synthesis. Synthesis of GNE-6640 is representative of the syntheses for
1 H NMR (400 MHz, CDCl 3 ) δ 8.04 (s, 1H), 7.33-7.23 (m, 0H), 4.93 (s, 2H), 2.93 (q, J = 7.5 Hz, 2H), 1.60 (s, 0H), 1.17 (t, J = 7.5 Hz, 3H). Liquid chromatography-mass spectrometry (LC-MS) (electro spray ionization (ESI) m/z): 264.1 (M + H + ). 3Bromo4ethylpyridin2amine: into a 500ml threenecked roundbottom flask purged and maintained with an inert atmosphere of nitrogen was placed 3,5dibromo4ethylpyridin2amine (18 g, 64.29 mmol) in tetrahydrofuran (300 ml). To this was added a solution of nbutyllithium (in hexane) (58 ml, 2.2 mol l −1 ) at − 78 °C. The resulting solution was stirred at − 78 °C for 1 h, quenched by the addition of 450 ml NH 4 Cl and then extracted with ethyl acetate (2 × 500 ml). The combined organic layers were washed with brine (2× 500 ml), dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by flash and preparative HPLC to afford 12 g (93%) of the title compound as a white solid. . 4Ethyl3(4methoxyphenyl)pyridn2amine: into a 500ml threenecked roundbottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of 3bromo4ethylpyridin2amine (12 g, 59.68 mmol) in CH 3 CN (100 ml), (4methoxyphenyl)boronic acid (11 g, 72.39 mmol), Na 2 CO 3 (120 ml, sat.), and Pd(dppf)Cl 2 (1.2 g, 1.64 mmol). The resulting solution was stirred at 110 °C for 1 h, diluted with of 500 ml of ethyl acetate, and then extracted with ethyl acetate (2 × 500 ml). The combined organic layers were washed with brine (3 × 200 ml), dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was purified on a silica gel column eluting with ethyl acetate/petroleum ether (1:100 to 1:10) to afford 10 g (73%) of the title compound. . 5Bromo4ethyl3(4methoxyphenyl)pyridin2amine: into a 250ml three necked roundbottom flask purged and maintained with an inert atmosphere of nitrogen were placed 4ethyl3(4methoxyphenyl)pyridn2amine (10 g, 43.80 mmol), tetrahydrofuran (THF) (100 ml), followed by NBS (7.8 g, 43.83 mmol) at 0 °C. The resulting solution was stirred at room temperature for 15 min, diluted with 500 ml EtOAc and 500 ml H 2 O. The resulting solution was extracted with ethyl acetate (2 × 500 ml). The organic layers were combined, washed with brine (2 × 500 ml), and concentrated under vacuum. The residue was purified on a silica gel column eluting with ethyl acetate/petroleum ether (1:20 to 1:10) to afford 8 g (59%) of the title compound. . 4(2Amino5bromo4ethylpyridin3yl)phenol: into a 250ml threenecked roundbottom flask purged and maintained with an inert atmosphere of nitrogen was placed 5bromo4ethyl3(4methoxyphenyl)pyridin2amine as a white solid (8 g, 26.04 mmol), dichloromethane (100 ml), followed by tribromoborane (19.6 g, 78.24 mmol) at 0 °C. The resulting solution was stirred at room temperature for 1 h and then quenched by the addition of 100 ml of NaHCO 3 (1 M) at 0 °C. The solids were collected by filtration and then washed with 100 ml H 2 O and 300 ml of ethyl acetate/petroleum ether (1:1) to afford 6.3 g (83%) of the title compound as a white solid. 
into a 250ml threenecked roundbottom flask purged and maintained with an inert atmosphere of nitrogen were placed 4(2amino5bromo4ethylpyridin3yl) phenol (1.0 g, 3.41 mmol,), 6(tetramethyl1,3,2dioxaborolan2yl)2Hindazole (880 mg, 3.41 mmol,), potassium carbonate (3.3 g, 23.88 mmol), water (30 ml), 1,4dioxane (25 ml), and Pd(dppf)Cl 2 (200 mg, 0.3 mmol). The resulting solu tion was stirred at 80 °C for 16 h, and diluted with 500 ml H 2 O and 500 ml ethyl acetate. The organic layer was washed twice with brine (2 × 250 ml) and concen trated under vacuum. The residue was purified on a silica gel column eluting with DCM/CH 3 OH (20:1-10:1) to afford the title compound.
1 H NMR (400 MHz, DMSOd 6 ) δ 13.07 (s, 1H), 9.52 (s, 1H), 8.07 (d, J = 1.0 Hz, 1H), 7.74 (s, 1H), 7.65 (dd, J = 1.6, 0.8 Hz, 1H), 7.56 (dt, J = 8.6, 0.9 Hz, 1H), 7.28 (dd, J = 8.5, 1.6 Hz, 1H), 7.10-7.04 (m, 2H), 6.92-6.86 (m, 2H), 4.94 (s, 2H), 2.26 (q, J = 7.4 Hz, 2H), 0.60 (t, J = 7.4 Hz, 3H).
13
C NMR (150 MHz, DMSOd 6 ) δ 15. 0, 24.0, 111.3, 117.4, 122.2, 122.3, 124.0, 127.8, 129.3, 130.2, 132.2, 135.3, 140.2, 147.2, 151.8, 157.2, 157.4 38.8, 41.4, 131.6, 136.6, 137.1, 138.8, 141.5, 146.4, 152.5, 154.1, 161.1, 163.1, 164.2, 171.3 26.6, 57.7, 73.4, 115.0, 119.5, 127.0, 128.3, 129.4, 129.7, 130.5, 135.7, 137.5, 147.0, 148.4, 156.1, 156. 
C NMR (150 MHz, DMSOd 6 ) δ 14. 3, 22.8, 116.2, 116.7, 120.0, 120.2, 120.6, 124.0, 124.7, 126.7, 127.8, 131.0, 136.3, 146.7, 148.9, 156.8, 157. 
C NMR (150 MHz, DMSOd 6 ) δ 13. 8, 23.1, 55.2, 111.0, 116.0, 119.6, 120.2, 123.6, 126.7, 127.6, 128.8, 130.8, 131.6, 146.7, 149.5. 156.7, 156.8, 156.9 22.6, 115.9, 116.0, 119.8, 125.9, 126.4, 126.5, 128.2, 128.5, 130.7, 130.8, 132.3, 133.2, 134.2, 139.1, 146.7, 148.4, 156.7, 157.2 H NMR (400 MHz, DMSOd 6 ) δ 9.53 (s, 1H), 7.98 (d, J = 6.1 Hz,1H), 7.95-7.87 (m, 2H), 7.72 (s, 1H), 7.43-7.31 (m, 3H), 7.14-6.95 (m, 2H), 6.93-6.74 (m, 2H), 5.04 (s, 2H), 2.33 (q, J = 7.4 Hz, 2H), 0.61 (t, J = 7.5 Hz, 3H).
C NMR (150 MHz, DMSOd 6 ) proton correlated carbon chemical shifts δ 14.9, 42.6, 113.9, 116.7, 116.7, 129.0, 131.3, 131.4, (15.0, 25.9, 29.0 
. impurities). LC-MS (ESI
1 H NMR (400 MHz, DMSOd 6 ) δ 9.53 (s, 1H), 7.98 (d, J = 6.1 Hz, 1H), 7.95-7.87 (m, 2H), 7.72 (s, 1H), 7.43-7.31 (m, 3H), 7.14-6.95 (m, 2H), 6.93-6.74 (m, 2H), 5.04 (s, 2H), 2.33 (q, J = 7.4 Hz, 2H), 2.06 (s, 2H), 0.61 (t, J = 7.5 Hz, 3H).
13
C NMR (150 MHz, DMSOd 6 ) δ 13.7, 23.9, 24.0, 120.0, 121.2, 125.6, 127.4, 129.2, 129.7, 130.2, 134.7, 136.9, 140.1, 140.3, 157.5, 168.8 GNE-0956, GNE-2090 , GNE-2143 , and GNE-2148 Synthesis of 9chloroN(5chloro2,4dimethoxyphenyl)N(cyanomethyl) 5,6,7,8tetrahydroacridine3carboxamide (GNE6831): 9Chloro5,6,7,8 tetrahydroacridine3carboxylic acid (100 mg, 0.38 mmol) was dissolved in 2 ml of N,Ndimethylformamide (DMF) and charged with 1[bis(dimethylamino)methy lene]1H1,2,3triazolo[4,5b]pyridinium 3oxide hexafluorophosphate (HATU) (144 mg, 0.38 mmol). After stirring at room temperature for 30 min, the mixture was then charged with 3((5chloro2,4dimethoxyphenyl)amino)propanenitrile (91 mg, 0.38 mmol). The resulting solution was stirred at 110 °C for 1 h, diluted with of 50 ml of ethyl acetate, and then extracted with ethyl acetate (2 × 100 ml). The combined organic layers were washed with brine (3 × 200 ml), dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was puri fied on a silica gel column eluting with ethyl acetate/petroleum ether (1:100 to 1:10) to afford the title compound (110 mg, 0.30 mmol, 78% yield) of the title compound. 27.0, 33.5, 37.4, 56.4, 56.4, 98.1, 111.7, 116.3, 122.7, 123.0, 125.1, 125.8, 127.8, 129.7, 130.3, 135.6, 139.8, 144.8, 154.5, 155.3, 160.6, 170.0 21.8, 22.2, 27.0, 33.5, 40.2, 54.6, 56.1, 56.3, 80.0, 80.2, 97.8, 111.4, 122.7, 124.3, 124.4, 125.8, 126.7, 129.6, 129.8, 137.7, 139.8, 145.0, 154.2, 154.7, 160.3, 170 22.4, 22.4, 27.5, 34.1, 56.6, 56.7, 56.8, 64.7, 98.1, 98.3, 123.2, 126.4, 127.4, 129.6, 129.8 0, 27.0, 33.5, 49.7, 52.6, 57.9, 58.4, 123.5, 125.5, 125.9, 126.5, 137.9, 139.9, 145.5, 160.4, 170.0 27.0, 33.6, 34.5, 44.5, 48.5, 52.3, 66.0, 123.9, 125.4, 126.0, 126.5, 129.8, 137.0, 140.0, 145.4, 160.6, 166,0 169.7 
Synthesis of GNE-0300 is representative of the syntheses for GNE-8735.
Synthesis of (1S)1(5bromo1Hindol2yl)N(2phenylethyl)ethanamine (GNE0300): 1(5bromo1Hindol2yl)ethan1one (90 mg, 0.38 mmol) was dis solved in 2 ml of DMF and charged with (S)phenethylamine (46 mg, 0.38 mmol). After stirring at room temperature for 30 min, the mixture was diluted with 50 ml ethyl acetate and 50 ml water. The mixture was partitioned and the organic was collected. The aqueous layer was then extracted with ethyl acetate (2 × 100 ml). The combined organic layers were washed with brine (3 × 200 ml), dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was puri fied on a silica gel column eluting with ethyl acetate/petroleum ether (1:100 to 1:10) to afford the title compound (120 mg, 0.35 mmol, 92% yield). 1 H NMR (400 MHz, DMSOd 6 ) δ 11.05 (s, 1H), 7.59 (d, J = 1.9 Hz, 1H), 7.30-7.19 (m, 3H), 7.20-7.06 (m, 6H), 6.21 (d, J = 1.8 Hz, 1H), 3.93 (q, J = 6.6 Hz, 1H), 2.77-2.56 (m, 4H), 1.36 (d, J = 6.6 Hz, 3H).
13
C NMR (150 MHz, DMSOd 6 ) δ 22. 5, 36.5, 49.3, 51.6, 98.0, 111.5, 113.4, 122.0, 123.1, 126.3, 128.7, 129.0, 130.3, 135.1, 140.8, 146 25.7, 28.3, 32.6, 36.0, 49.3, 55.6, 110.7, 112.8, 119.7, 122.1, 125.8, 128.2, 128.6, 130.3, 132.5, 140.5 (Z)2,3,6,7tetrahydro1Hazepine hydrochloride: 4 N hydrogen chloride in 1,4dioxane (250 ml; 1 mol) was added over 5 min to a stirred, icecooled solution of (Z)tertbutyl 2,3,6,7tetrahydro1Hazepine1carboxylate (50 g; 0.254 mol) in methanol (250 ml). On complete addition, the ice bath was removed and stirring continued at room temperature for 3.75 h. Volatiles were removed under reduced pressure and the residue triturated twice with diethyl ether (300 ml) to afford (Z)2,3,6,7tetrahydro1Hazepine hydrochloride as a pale pink solid (32.3 g; 95%). 1 HNMR (DMSOd 6 , 400 MHz) δ 9.54 (br s, 2H), 6.40-6.25 (m, 2H), 3.1-3.05 (m, 4H), 2.55-2.40 (m, 4H).
(Z)1(1methyl4nitro1Hpyrazol5yl)2,3,6,7tetrahydro1Hazepine: a mixture of (Z)2,3,6,7tetrahydro1Hazepine hydrochloride (32.3 g; 0.24 mol), 5chloro1methyl4nitro1Hpyrazole (37.2 g; 0.23 mol), potassium fluoride (56.24 g; 0.96 mol), and diisopropylethylamine (64 ml; 0.362 mol) in anhydrous DMSO (650 ml) was heated at 75 °C for 21 h. On cooling, the mixture was poured into water (1,500 ml), extracted with ethyl acetate (4 × 500 ml), and the combined organics washed with water (2 × 400 ml) and brine (300 ml) then dried (MgSO 4 343 mol) was added portionwise over 10 min to a stirred, icecooled solution of (Z)1(1methyl 4nitro1Hpyrazol5yl)2,3,6,7tetrahydro1Hazepine (50.74 g; 0.23 mol) in dichloromethane (1,000 ml). An ice bath was used to control the minor exotherm observed during a smallerscale reaction. On complete addition, the ice bath was removed and stirring continued at room temperature for 18 h. The reaction mixture was washed with saturated sodium hydrogen carbonate (750 ml), 1 N sodium hydroxide (2 × 500 ml), and brine (350 ml Rel(4R,5R)5azido1(1methyl4nitro1Hpyrazol5yl)azepan4ol: to a stirred solution of 4(1methyl4nitro1Hpyrazol5yl)8oxa4azabicyclo[5.1.0] octane (29.28 g) in methanol (350 ml) and water (90 ml) was added ammonium chloride (16.5 g; 0.308 mol) followed by sodium azide (20 g; 0.307 mol). The mixture was heated behind a blast screen at 70 °C for 22 h, cooled, then concen trated to 100 ml under reduced pressure at 40 °C. The concentrated solution was poured into water (1,300 ml), extracted with dichloromethane (4 × 400 ml), and the combined organics dried (MgSO 4 ). Evaporation under reduced pressure at 35 °C gave rel(4R,5R)5azido1(1methyl4nitro1Hpyrazol5yl)azepan4ol (antiisomer and a racemic mixture) as a pale yellow oil (34.5 g; 96% over two steps Rel(4R,5R)4azido5fluoro1(1methyl4nitro1Hpyrazol5yl)azepane: fifty per cent deoxofluor in THF (111 ml; 0.307 mol) was added slowly over 20 min to a stirred, icecooled solution of rel(4R,5R)5azido1(1methyl4 nitro1H pyrazol5yl)azepan4ol (32.5 g; 0.115 mol) in dichloromethane (500 ml). On complete addition, the ice bath was removed and stirring continued at room temperature for 20 h. The reaction mixture was recooled in an ice bath and saturated sodium hydrogen carbonate (400 ml) added dropwise (note this reac tion is effervescent). After stirring for 30 min, the layers were separated and the aqueous layer extracted with dichloromethane (2 × 500 ml). Pooled organics were dried (MgSO 4 ) and the solvent removed under reduced pressure. Flash column chromatography on silica eluting with 0-100% ethyl acetate in isohexane gradient afforded rel(4R,5R)4azido5fluoro1(1methyl4nitro1Hpyrazol5yl)aze pane as a pale orange oil (26 g; 80%). Rel(4R,5R)5fluoro1(1methyl4nitro1Hpyrazol5yl)azepan4amine: a mixture of rel(4R,5R)4azido5fluoro1(1methyl4nitro1Hpyrazol5yl) azepane (26 g; 91.8 mmol) and triphenylphosphine (24.1 g; 92 mmol) in tetrahy drofuran (400 ml) and water (80 ml) was heated at 60 °C for 20 h, cooled and con centrated to approximately 80 ml under reduced pressure. Ethyl acetate (500 ml) was added and the mixture extracted with 1 N HCl (4 × 125 ml). Pooled acidic extracts were washed with ethyl acetate (500 ml), basified to pH 14 with 6 N NaOH, and extracted with dichloromethane (3 × 400 ml). Combined extracts were dried (MgSO 4 ) and the solvent removed under reduced pressure to give rel(4R,5R)5 fluoro1(1methyl4nitro1Hpyrazol5yl)azepan4amine as a pale yellow oil (22 g; 93%). . tertButyl (4R,5R)5fluoro1(1methyl4nitro1Hpyrazol5yl)azepan4 ylcarbamate: ditertbutyl dicarbonate (28 g; 128.3 mmol) was added to a stirred, icecooled solution of rel(4R,5R)5fluoro1(1methyl4nitro1Hpyrazol 5yl)azepan4amine (22 g; 85.6 mmol) and diisopropylethylamine (22.4 ml; 128.6 mmol) in dichloromethane (600 ml). On complete addition, the ice bath was removed and stirring continued at room temperature for 20 h. The reaction mixture was washed with saturated sodium hydrogen carbonate (500 ml) and the aqueous layer reextracted with dichloromethane (2 × 300 ml). Pooled organics were dried (MgSO 4 ) and the solvent removed under reduced pressure. Flash column chromatography on silica eluting with 0-100% ethyl acetate in isohexane gradient afforded a pale yellow solid (29.7 g; 97%). Chiral separation of the racemic Letter reSeArCH mixture by supercritical fluid chromatography using a Chiralpak IA column with an isocratic mobile phase of 15% methanol (with 0.1% NH 4 OH) in carbon dioxide gave the desired product (second peak) as a single enantiomer. . tertButyl (4R,5R)5fluoro1(4amino1methyl1Hpyrazol5yl) azepan 4ylcarbamate: to a stirred solution of tertbutyl (4R,5R)5fluoro1(1methyl 4nitro1Hpyrazol5yl)azepan4ylcarbamate (15.0 g; 42 mmol) in ethanol (1,000 ml) and water (100 ml) was added ammonium chloride (11.34 g; 210 mmol) and iron powder (9.4 g; 168 mmol). The mixture was heated at 99 °C for 2.75 h, cooled, filtered through Celite and evaporated to approximately 100 ml. The concentrate was diluted with water (1,000 ml) and extracted with ethyl acetate (2 × 500 ml). The pooled extracts were washed with water (200 ml), dried (MgSO 4 ) and the solvent removed under reduced pressure to give tertbutyl (4R,5R)5 fluoro1(4amino1methyl1Hpyrazol5yl)azepan4ylcarbamate as a pale brown solid (12.6 g; 91%). . tertButyl (4R,5R)1(4(5tertbutoxycarbonylamino2(2,6difluorophenyl) thiazole4carboxamido)1methyl1Hpyrazol5yl)5fluoroazepan4ylcarbamate: a mixture of tertbutyl (4R,5R)5fluoro1(4amino1methyl1Hpyrazol5yl) azepan4 ylcarbamate (12.6 g, 38.5 mmol), 5(tertbutoxycarbonylamino)2(2,6 difluorophenyl)thiazole4carboxylic acid (14.4 g, 40.4 mmol), diisopropyleth ylamine (13.4 ml, 77 mmol), and PyBOP (26.1 g, 50 mmol) in dichloromethane (400 ml) was stirred at room temperature for 48 h. Saturated sodium hydrogen carbonate (600 ml) was added and stirring continued for 30 min. The mixture was filtered, the layers separated and the aqueous layer extracted with dichlorometh ane (500 ml). The pooled organics were dried (MgSO 4 ) and the solvent removed under reduced pressure. Flash column chromatography on silica eluting with 0-100% ethyl acetate in isohexane gradient afforded tertbutyl (4R,5R)1 (4(5tertbutoxycarbonylamino2(2,6difluorophenyl)thiazole4carboxamido)1 methyl1Hpyrazol5yl)5fluoroazepan4ylcarbamate as a pale yellow solid (2.5 g, 9.8%). Further elution with 0-10% methanol in ethyl acetate, then 10% methanol in dichloromethane, evaporation of relevant fractions under reduced pressure, and trituration of the residue with cold diethyl ether gave a further 7.61 g (30%) of product. 5AminoN(5((4R,5R)4amino5fluoroazepan1yl)1methyl1Hpyrazol 4yl)2(2,6difluorophenyl)thiazole4carboxamide (GDC0339): tertbutyl (4R,5R)1(4(5tertbutoxycarbonylamino2(2,6difluorophenyl)thiazole4 carboxamido)1methyl1Hpyrazol5yl)5fluoroazepan4ylcarbamate (10.11 g, 15.2 mmol) in 4 N HCl in dioxane (200 ml) and methanol (200 ml) was stirred at room temperature for 20 h. Evaporation under reduced pressure afforded a pale brown solid which was dissolved in 50% methanol in dichloromethane and added to a strong cation exchange (SCX) chromatography cartridge. After washing with dichloromethane and methanol, elution with 1 N ammonia in methanol and evaporation of the eluent under reduced pressure afforded 5aminoN(5((4R,5R)4amino5fluoroazepan 1yl)1methyl1Hpyrazol4yl)2(2,6difluorophenyl)thiazole4carboxamide as the free base (6.3 g, 89% yield). Purity by a 30min LC-MS at ultraviolet 254 nm: 98. 7, 33.6, 35.9, 46.4, 48.9, 55.5, 98.4, 111.4, 112.7, 112.9 113.1, 122.7, 131.6, 132.6, 133.9, 142.0, 158.7, 159.8, 162.5 General methods: unless otherwise noted, reactions were conducted using commercially available reagents and solvents, which were used as received. Hydrogenation reactions were performed in a ThalesNano HCube reactor using 30mm 10% Pd/C catalyst cartridges. Silica gel chromatography was per formed using a Biotage Isolera Four flash purification system with Silicycle SiliaSep cartridges. tertButyl (3R)3[(2S)2{[(benzyloxy)carbonyl]amino}3phenylpropan amido]pyrrolidine1carboxylate: to a solution of Cbzlphenylalanine (0.9 g, 3.00 mmol) in dichloromethane (25 ml) were sequentially added HOBt monohy drate (0.46 g, 3.00 mmol) and EDAC (0.58 g, 3 mmol). To this mixture was added a solution of tertbutyl (3R)3aminopyrrolidine1carboxylate (0.56 g, 3.00 mmol). The reaction was stirred at ambient temperature for 18 h, then partitioned between dichloromethane and 5% aqueous citric acid. The layers were separated, and the organic phase was washed with aqueous saturated NaHCO 3 and brine, dried over MgSO 4 , filtered, and concentrated. The crude concentrate was purified by flash silica gel chromatography (25 g Silicycle column), eluting with ethyl acetate in hexanes (20-80%) to provide 1.27 g (91%) of the title compound. 108) in tetrahydrofuran (0.5 ml) were added 3phenylpropanoyl chloride (0.016 ml, 0.108 mmol) and DIPEA (0.02 ml, 0.108 mmol). The reaction was stirred at ambient temperature for 90 min and concentrated under reduced pressure to obtain crude tertbutyl (3R)3[(2S)3 phenyl2(3phenylpropanamido)propanamido]pyrrolidine1carboxylate that was used without further purification.
To the crude tertbutyl (3R)3[(2S)3phenyl2(3phenylpropanamido) propanamido]pyrrolidine1carboxylate in dichloromethane (1.0 ml), were added triethylsilane (1 ml), water (3 ml), and trifluoroacetic acid (0.5 ml). The reaction was stirred at ambient temperature for 90 min, concentrated under reduced pressure, and triturated with hexanes:diethyl ether (1:1) to obtain (2S)3phenyl 2(3phenylpropanamido)N[(3R)pyrrolidin3yl]propanamide as a trifluoro acetic acid salt.
To (2S)3phenyl2(3phenylpropanamido)N[(3R)pyrrolidin3yl]propan amide trifluoroacetic acid in acetonitrile (0.7 ml) were sequentially added DIPEA (0.07 ml, 0.4 mmol) and cyanogen bromide (2.0 M in MeCN, 0.05 ml, 0.1 mmol). The reaction was stirred at ambient temperature for 30 min and then diluted with dichloromethane. The diluted reaction was washed sequentially with water, 10% aqueous KHSO 4 , and brine. The organic layer was dried over MgSO 4 , filtered, and concentrated. The crude concentrate was purified by flash silica gel chroma tography (4 g Silicycle column), eluting with acetone/dichloromethane to obtain 25 mg (64%) of the title compound 9, 31.0, 36.7, 38.2, 48.3, 48.7, 53.7, 54.5, 117.2, 125.8, 126.3, 128.0, 128.1, 128.2, 129.2, 137.5, 141.3, 171.0, 171 
Hit-to-lead selection cascade assays. Biochemical deubiquitinase assays.
Biochemical deubiquitinase assays used ubiquitinRho110 as a substrate to enable kinetic monitoring of reactions for USP7, USP7 catalytic domain, USP5, and USP47. The deubiquitinase proteins and their concentrations that were used in biochemical reactions were as follows. USP7, fulllength Nterminal Histag, native C terminus: 0.18 nM (Genentech, Hs_USP7 21102); USP7 catalytic domain Nterminal Histag: 40 nM (Genentech, Hs_USP7.K208K554); USP5, fulllength: 0.5 nM (Boston Biochem catalogue number E322, lot 02010210); USP47, full length Nterminal Histag:0.8 nM (Genentech Hs_USP47.M1D1287). Substrate K m values for USP proteins were USP7 fulllength, 2 μ M; USP5 fulllength, 0.33 μ M; and USP47 fulllength, 0.175 μ M. The final assay conditions were as follows. The reaction buffer consisted of 50 mM Tris (pH 7.5), 0.01%(v/v) Triton X100, 2.5 mM dithiothreitol, and 0.1% (w/v) bovine gamma globulin (Sigma catalogue number G500925G). The final substrate ubiquitinRho110 (Boston Biochem catalogue number U555) concentration used for reactions was 1 μ M. Reactions were per formed for 1 h at room temperature, in black 20 μ lvolume polystyrene ProxiPlate 384 F Plus (PerkinElmer catalogue number 6008260). Test compounds, including a control USP7 inhibitor (Ubaldehyde, Boston Biochem catalogue number U201), were serially diluted in DMSO, in 384well clear Vbottom polypropylene plates (Greiner catalogue number 781280). Compounds in DMSO were diluted tenfold into reaction buffer, to achieve threefold the final desired concentration.
Letter reSeArCH
The substrate, ubiquitinRho110 (Boston Biochem catalogue number U555), was prepared at 3 μ M (threefold the final concentration) and 5 μ l was dispensed into the reaction plate. Five microlitres of the compounds (diluted in reaction buffer at threefold the final concentration) were transferred to the reaction plate. Five micro litres of DUB protein, which was diluted in reaction buffer at threefold the final concentration, was transferred to the reaction plate to initiate the reaction. After 1 h incubation at room temperature, the reaction was quenched by the addition of 5 μ l of 400 mM acetic acid, in the case of an endpoint reaction. The enzymatic product was measured by quantifying the fluorescence signal of cleaved Rhodamine110 using excitation at 485 nm and emission at 535 nm. When preincubation of DUB with compounds was required, the order of addition of reagents was modified to premix the compounds with DUB (with a 1 h incubation period), before the addi tion of the substrate and the initiation of the reaction period. Percentage inhibition values were calculated relative to a noenzyme control and an uninhibited enzyme control. Curve fitting and IC 50 calculations were performed using Genedata Screener software. Conversion between IC 50 and K i values was performed using the Cheng-Prusoff equation. Cellular ubiquitin-MDM2 assay. HCT116 colon cancer cells or SJSA1 osteo sarcoma cells were seeded at a density of 150,000 cells per well in 90 μ l RPMI 1640 medium, 10% FBS (or 0.5% FBS for low serum conditions), 1× GlutaMAX (Gibco) in 96well black clear bottom, tissueculturetreated microplates (Greiner, catalogue number 655090), and incubated for 2 h at 37 °C, 5% CO 2 in a tissue culture incubator. Compounds were prepared in a serial dilution in DMSO at 200× the final desired concentration in a 96well polypropylene Vbottom microplate (Greiner, catalogue number 651261), then diluted 1:20 in RPMI tissue culture medium and 10 μ l transferred to each well of the cell plate. Cell plates were incu bated overnight for 20 h, at 37 °C, 5% CO 2 . Twenty microlitres of a 120 μ M stock (in RPMI) of the proteasome inhibitor MG132 (Cayman Chemical, catalogue num ber 10012628) was added to each well. Cells were incubated for 1 h at 37 °C, 5% CO 2 . Quantification of ubiquitin-MDM2 was performed using a Ub/total MDM2 wholecell lysate kit (MSD, catalogue number K15168D2). Cells were lysed by adding 15 μ l of 5× MSD lysis buffer (containing additives: 10 mM NaF, 10 mM β glycero phosphate, 1.5 mM Na 3 VO 4 , protease inhibitor cocktail (Sigma, P8340)) to each well and incubated at 4 °C for 30 min with shaking. One hundred microlitres of lysate were transferred to each well of the MSD 96well plate and incubated at room temperature for 1 h while shaking (650 r.p.m.) in the dark. The MSD plates were washed three times in Trisbuffered saline (50 mM TrisCl, pH 7.5, 150 mM NaCl) using a Biotek EL405 plate washer. Three millilitres of detection antibody solution were prepared per plate (1 ml of block buffer A, 1.82 ml 1× Tris wash buffer, 150 μ l 2% Blocker DM, 30 μ l 10% Blocker DR, 60 μ l 50× antitotal MDM2 antibody). Twentyfive microlitres of detection antibody solution were added per well and incubated for 1 h at room temperature (650 r.p.m.) in the dark. Plates were washed three times in Trisbuffered saline using a Biotek EL405 plate washer. MSD read buffer was prepared according to the manufacturer's instructions and 150 μ l added per well. Plates were read using a MSD Sector Reader. The final meas urement was the ratio of ubiquitinated MDM2 to total MDM2. The percentage increase in ubiquitin-MDM2 was calculated relative to DMSO controls using Genedata Screener software. Total MDM2 immunofluorescence. HCT116 cells were seeded at a density of 40,000 cells per well in 384well tissue culture plates (Greiner 781091) in 50 μl per well of RPMI, 10% FBS, 2 mM lglutamine, and incubated overnight. Test compounds were prepared in a 20point serial dilution (one to twofold) in DMSO using a Biomek FX in a 384well Labcyteapproved polypropylene plate (Labcyte P05525). Compounds were acoustically dispensed into the cell plates using a Labcyte Echo (final total volume transferred was 50 nl) (DMSO final concentration was 0.1% v/v). Cell plates were incubated at 37 °C, 5% CO 2 , for 24 h. Cells were fixed by addition of 15 μ l of 16% paraformaldehyde (Electron Microscopy Sciences 15710 S) directly to the 50 μ l cell culture medium in each well. Plates were incubated for 30 min at room temperature. The well contents were aspirated using a Biotek EL406 and 50 μ l per well of permeabilization/block buffer added (phosphatebuffered saline (PBS, pH 7.5), Triton X100 0.5% (v/v), BSA 0.5% (w/v), proclin 15 p.p.m.). Plates were incubated for 30 min then washed three times with 100 μ l per well of PBS. Twentyfive microlitres per well of antiMDM2 (rabbit polyclonal, AbCam ab58530 diluted 1:500 in PBS, BSA 0.5% (w/v), Triton X100 0.1% (v/v)) were dispensed into each well. Plates were incubated for 2 h at room temperature then washed four times with 100 μ l per well of PBS using a Biotek EL406. Twenty five microlitres per well of Alexafluor 555 conjugated antirabbit IgG (Life Technologies A31572, diluted 1:1,000 and Hoechst 33342 1 μ g ml −1 diluted in PBS, BSA 0.5% (w/v), Triton X100 0.1% (v/v)) were dispensed into each well. Plates were incubated for 2 h at room temperature then washed four times with 100 μ l per well of PBS using a Biotek EL406. Fluorescence images of the samples (channel 1: 38623_BGRFRN_ BGRFRN (DNA); channel 2: 54915_BGRFRN_ BGRFRN (MDM2)) were acquired using a Cellomics XTI Arrayscan with the Bioapplication 'Compartmental Analysis' . Channel 1 was used to define the nuclear region. Measurements were made of 'Mean_CircAvgIntCh2' , which was the Alexa Fluor 555 fluorescence intensity (MDM2) within the nuclear region measured on a percell basis and averaged over all the measured cells. Data analysis and EC 50 calculation were performed in GraphPad Prism using nonlinear fourparameter curve fitting. Cathepsin-B protease assay. CathepsinB proteolytic activity was quantified by an LC-MS, MRMbased detection method. In brief, varying concentrations of experi mental compound were incubated with 0.5 nM human liver cathepsinB (EMD Millipore, 219364) and benzyloxycarbonylArgArg7amino4 methylcoumarin (CbzRRAMC) fluorogenic substrate in buffer containing 10 mM MES pH 6.0 and 1 mM DTT. The reaction was incubated for 5 min at room temperature, followed by quenching with the addition of an equal volume of 2% formic acid in water. Free AMC liberated by cathepsinB was quantified on a Sciex 5500 QTRAP mass spectrometer (Sciex) equipped with a Biocius Rapidfire highthroughput LC system (Agilent). AMC product was captured on an Agilent C18 Rapidfire cartridge, desalted with a 0.1% formic acid wash, and then eluted with 80% acetonitrile, 0.1% formic acid. Measured MRM areaundercurve for AMC was plotted against compound concentration using GraphPad Prism and fitted for IC 50 using fourparameter fitting. MRM parameters for AMC were as follows: ESI positive mode, Q1 = 233.1, Q3 = 175.2, collision energy = 16. Caspase-3 protease assay. Caspase3 proteolytic activity was quantified by an LC-MS, MRMbased detection method. In brief, varying concentrations of exper imental compound were incubated with 0.025 nM of recombinant caspase3 (cloned and purified inhouse) and 1 μ M (ZDEVD) 2 Rho110 fluorogenic substrate in buffer containing 25 mM HEPES, pH 7.2, and 5 mM DTT. The reaction was incubated for 20 min at room temperature, followed by quench ing with the addition of an equal volume of 2% formic acid in water. Free ZDEVD liberated by caspase3 was quantified on a Sciex 5500 QTRAP mass spectrometer (Sciex) equipped with a Biocius Rapidfire highthroughput LC system (Agilent). ZDEVD product was captured on an Agilent C18 Rapidfire cartridge, desalted with a 0.1% formic acid wash, then eluted with 80% acetonitrile, 0.1% formic acid. Measured MRM areaundercurve for ZDEVD was plotted against compound concentration using GraphPad Prism and fitted for IC 50 using fourparameter fitting. MRM parameters for ZDEVD were as follows: ESI negative mode, Q 1 = 609.2, Q 3 = 440.2, collision energy = − 35. USP7 aggregation analysis. Aggregation of fulllength USP7 was confirmed by dynamic light scattering using a Wyatt DynaPro Plate Reader. Dynamic light scattering data were acquired at 37 °C, with Dynamics V7 software, with a 10 s acquisition time, ten acquisitions per measurement in autoattenuation mode. Compounds were present at 100 μ M in a buffer containing 50 mM HEPES pH 7.2, 150 mM NaCl, 0.01% Triton X100, 1 mM TCEP, 0.1% DMSO. Fulllength USP7 was present at 1 mg ml −1 with all compounds except rottlerin. Aggregate is defined here as having a hydrodynamic radius greater than 10 nm.
USP7 covalent modification and LC-MS analysis.
To evaluate potential covalent modification of the proteins, fulllength USP7 was incubated with excess com pound at room temperature overnight and covalent modification was evaluated by LC-MS using standard methods. Cell culture and cell treatments. HCT116 parental, USP7null (HD R02028), and HCT116 p53null (HD 104001) cell lines were purchased from Horizon. All other cell lines were obtained from Genentech's repository and were cultured in standard conditions in RPMI medium containing 10% FBS (solid tumour cell lines) or 20% FBS (haematopoietic cell lines), 1% penicillin/streptomycin, and 1% lglutamine. All cell lines were mycoplasmatested and cell line identity was confirmed by short tandem repeat and single nucleotide polymorphism profiling as described 24 . For studies evaluating cellular effects of compound treatments, 2,500-5,000 cells were seeded in one well of a 96well plate (Corning 3904). The following day, the medium was changed from normal (10%) to low serum (0.5%) containing vehicle (DMSO) or compounds. Sixteen to 24 h later, FBS was added to each well to bring serum levels back to 10%. Cells were then allowed to grow for 2 additional days. All treatments were done in triplicate. For degradation rescue studies, the proteasome inhibitor bortezomib (Selleckchem) or the UAE inhibitor MLN7243 (Active Biochem) was added at 5 μ M 30-45 min before collection. Cycloheximide chase studies. MCF7 cells were treated for a total of 7 h with DMSO or 15 μ M of the indicated compounds. During the 7 h of compound treatment, 50 μ M cycloheximide was added for the indicated times before collection. Cells were subsequently collected and lysates processed for western blot analysis. Antibodies and reagents. Antibodies to the indicated proteins were purchased from the following vendors: USP7 (ab84098), USP5 (ab84695) (AbCam) or (4833 Letter reSeArCH (2945), Mcl1 (4572), PIM2 (2730), cleavedcaspase3 (2664), phosphoS112Bad (5284), p21 (2947) (Cell Signaling Technology); K48 polyubiquitin (Genentech); USP47 (Bethyl A301190A); UCHL1 (Invitrogen 381000); HAHRP (clone HA7) and Flag (A8592) (Sigma); p53 (Thermo Scientific MS738P1); p21 (Millipore 05655), Bad (AF819) (R&D). Secondary antibodies were purchased from LICOR Biosciences or Jackson ImmunoResearch. Fulllength human USP7 was cloned into a pRK5 mammalian expression construct with a Cterminal Flagtag and muta tions were introduced by QuickChange sitedirected mutagenesis as instructed by the manufacturer (Agilent). Western blotting, quantification, immunoprecipitations, and deubiquitinase assays. Cells were treated with compounds as detailed above before lysis for western blot analysis. Primary antibodies were diluted 1:1,000 and incubated for 1 h at room temperature or 4 °C overnight. Secondary antibodies were diluted 1:10,000 and incubated for 30-60 min at room temperature. Blots were either imaged using a chemiluminescent reagent (Pierce) or were scanned and bands quantified using LICOR Odyssey instrumentation and software, respectively. Immunoprecipitations with ubiquitinspecific antibodies were performed as described 25 , and immuno precipitates and corresponding cell lysates were analysed by immunoblot analysis as previously described 25 using the antibodies detailed above. For in vitro deubi quitination of PIM2, ubiquitinated PIM2 was captured by treating MV411 cells for 45 min with the proteasome inhibitor MG132 (SelleckChem). Cells were washed, lysed in a 6 M urea lysis buffer, and antiK48 polyubiquitin immuno precipirates were washed and deubiquitinated with 250 nM wildtype or C223S fulllength recombinant USP7 following a similar protocol as described 25 .
Cell viability studies and analysis. IncuCyte live cell analysis. One day after cell seeding, 10% cell culture medium was changed to 0.5% serum medium containing 2 μ M CellEvent Caspase 3/7 reagent (Life Technologies C10423) and compounds. The plates were placed in an IncuCyte live cell imager and scanning was started within 15-20 min. Twentyfour hours later, 10% serum was added back to the cell cultures. Images were taken every 2 h for 68-72 h, using a 10× objective. Phase contrast was used to measure cell confluency/density and green fluorescence was used to measure caspase activity. The images were analysed using IncuCyte software (Basic Analysis parameters) and a ratio of caspase activity to cell density/ count was determined. For combination experiments, MCF7 cells were treated with 15 μ M USP7 inhibitors or 0.1 μ M doxorubicin alone or in combination. Similarly, U2OS cells were treated with 15 μ M USP7 inhibitors or 1 μ M cisplatin alone or in combination.
CellTiter-Glo assays with wild-type and USP7-null HCT-116 cells.
Cells were plated and cultured as described for IncuCyte studies. Seventytwo hours after compounds were added, CellTiterGlo (Promega) reagent was added following the vendor's protocol. Three times more USP7null HCT116 cells were plated per well than wildtype HCT116 cells (7,500 versus 2,500 cells), given the slower proliferation of USP7null cells. Tumour cell-line panel viability. GNE6640 and GNE6641 were profiled for 3 days across 441 cell lines, and GNE6776, GNE6640, and GNE6641 were profiled for 5 days across a subset of 185 cell lines as previously described 26 . In brief, compounds were screened in ninepoint dose-response using a threefold dilution. Cells were seeded into 384well plates 24 h before compound addition. Cells were then incubated with compound for 72 h or 120 h before assaying viability (CellTiterGlo, Promega). Assays were performed in biological triplicate. Cells were incubated (37 °C, 5% CO 2 ) in RPMI1640, 2.5% FBS (72 h assay) or 5% FBS (120 h assay), and 2 mM glutamine throughout the assay. The reported IC 50 and mean viability metrics were as follows: IC 50 was the dose at which the estimated inhibition was 50% relative to untreated wells (that is, absolute IC 50 ). The mean viability was calculated as previously described 26 . Pharmacogenomics analysis. We determined genomic and nongenomic features that were associated with differences in compound sensitivity. Mean viability was calculated as the arithmetic average of the fitted viabilities at each tested dose, as described 26 . For this analysis, normalized mean viabilities of GNE 6640 and GNE6446 were determined by normalizing the mean viabilities of each compound by the mean viability of GNE6641. Cancer type, cell histology, loss offunction, and hotspot mutations were assessed for statistical association with changes in normalized mean viability. Lossoffunction protein coding mutations included (1) insertions, (2) deletions, and (3) substitutions resulting in predicted truncating, splice site, translational start site, or nonstop mutations present in more than 90% of reads sequenced (> 90% variant allele frequency). Hotspot missense mutations assessed here were previously reported as significantly recurrent mutations in a pancancer analysis 27 . Features present in at least three cell lines were assessed. Statistical significance was determined using a twosided Student's ttest. Q values were determined by correcting resulting P values for multiple hypothesis testing using the Benjamini-Hochberg procedure. Primary combination screen. A compound library comprising 589 compounds arrayed in ninepoint dose-response was screened in the absence or presence of fixed doses of GNE6776 (0 nm, 125 nM, 250 nM, 500 nM, 1,000 nM, and 2,000 nM) or GNE6640 (400 nM). In brief, 5,000 EOL1 cells were seeded into 384well plates, and compound was added 24 h later. Cell viability was deter mined 120 h after compound addition (CellTiterGlo). Curves were fitted, and both IC 50 and mean viability metrics were calculated. The IC 50 was the dose at which inhibition was 50% relative to untreated wells. The mean viability was the average of the fitted viabilities at each tested dose. Mean viability was equivalent to the area under the logdose/viability curve divided by the total number of tested doses. Mean viability values were used for the analysis described in Extended Data Fig. 6g . All data were fitted using Genedata Screener software. Primary combination screen analysis. Normalized mean viabilities were determined in the EOL1 cell line for 574 compounds that have known protein or mecha nistic targets, in the presence of DMSO or increasing concentrations of GNE 6776 (100 nM, 250 nM, 500 nM, 1,000 nM or 2,000 nM) or 400 nM of GNE6640. For each compound, we assessed the difference in mean viability between USP7 inhibitor treatment and the DMSO treatment. For targets targeted by three or more compounds, we calculated the enrichment of high mean viability difference for each concentration of USP7 inhibitor by using a Wilcoxon ranksum test. For visualization purposes, we combined the results of all concentrations by taking the mean of the − log 10 (transformed P values) for each target. Bliss analysis. PIM inhibitors were tested in a ninepoint dose-response matrix with GNE6676 in the same manner as described for the compound library screen. Inhibitors were screened in threefold dilution using a top concentration of 10 μ M for PIM inhibitors and 20 μ M for GNE6676. Bliss calculations were performed using Genedata Screener software and the synergy score was calculated as previously described 28 . Exome sequencing pipeline. Exome sequencing and analysis of the cell lines was performed using standard protocols and analysed by methods previously described 29 . FASTQ reads were aligned to the human reference genome (GRCh38) using GSNAP version '20131010' with the following parameters: M 2 n 10 B 2 i 1-pairmaxdna= 1,000-terminalthreshold= 1,000-gmapmode= none-clip overlap. Duplicate reads in the resulting BAM file were marked using PicardTools, and indels realigned using the GATK IndelRealigner tool. Variations were called using the Bioconductor package VariantTools version 1.9.4. with default options except for two exceptions: (1) no variants were called in repeat regions as defined by the annotation Dust, Satellite repeats, and Tandem repeats in EnsEMBl 77; and (2) the avgNborCount post filter was configured using all single nucleotide polymorphisms from dbSNP version 138. Deubiquitinase selectivity analysis. Recombinant deubiquitinase di-ubiquitin mass spectrometry cleavage assay. The MALDI-TOF DUB assay was performed using the indicated concentrations of recombinant deubiquitinases, diubiquitin substrates, and USP7 inhibitor compounds as described previously 4 . The inhibition efficiency for GNE6640 and GNE6776 against the UCHl family members was monitored on UbUbe2W (UbE2), an alternative substrate to diubiquitin. Endogenous deubiquitinase activity-based probe assay. HEK293T cells at 80% confluency were collected by rinsing the plate once with 10 ml PBS followed by scraping. Cells were cleared by spinning them for 3 min at 350g at 4 °C and cell pellets were flashfrozen in liquid nitrogen and stored at − 80 °C until lysis. Frozen pellets were lysed by quickly rethawing them in buffer A (50 mM TrisHCl pH 7.5, 250 mM sucrose, 1× phosphatase STOP, 2.5 mM TCEP, 2 mM ATP, 50 μ M phenylmethylsulfonyl fluoride (PMSF), 120 mM NaCl, 5 mM MgCl 2 ) and the lysate cleared by centrifugation by spinning at 18,000g at 4 °C. The protein concentration was adjusted to 5 mg ml
, and 5 mg (1 ml) each of this cell lysate was incubated with indicated compounds or DMSO at the indicated concentrations for 20 min at 900 r.p.m., 25 °C in a Thermomixer (Eppendorf AG). After compound incubation, 300 ng of recombinant viral DUB was added and lysates were incubated with 6.6 μ g ml −1 of the indicated activitybased DUB probe, at 1,250 r.p.m. and 25 °C, for the indicated times. The reaction was terminated by adding a 20% SDS solution to a final concentration of 0.4% for at least 30 min at room temperature, rotating. Subsequently, the lysate was diluted ten times with buffer B (50 mM TrisHCl pH 7.5, 150 mM NaCl, 5 mM EDTA, protease inhibitor cocktail EDTAfree (Roche), 50 μ M PMSF, 0.5 % NP40) into 15 ml conical tubes. About 120 μ l slurry of preequilibrated antiHA affinity matrix (Roche) was added and HAtagged proteins were immunopurified with this matrix by rotating the samples overnight at 4 °C. The beads were then washed 1 ml of icecold buffer B (three times), buffer B without NP40 (once), and TEAB (15 mM triethylam moniabicarbonate, pH 8.5) (three times). Spins between washes were performed at 2,000g at 4 °C. To elute the immunopurified material, 330 μ l of buffer C (1 mg ml −1 HA peptide (Thermo Scientific), 15 mM TEAB, 0.02 % Rapigest (Waters)) was added and the samples were incubated at 37 °C for 30 min at 1,100 r.p.m. shaking in a Thermomixer (Eppendorf AG). The eluted material was cleared from the beads by spinning at 2,600g. The cleared material was stored at − 80 °C until mass spectrometry preparation and analysis. For DUB identifications, the eluted proteins were digested with trypsin using filteraided sample preparation. Eluents were added to Microcon30K filtration devices (Millipore) and briefly washed by 0.2 ml of 8 M urea in 200 mM TEAB, pH 8.5. Between each step, liquid was cleared by centrifugation at 14,000g, except if noted. Proteins were reduced by DTT for 20 min at 60 °C and subsequently alkylated by iodoacetamide for 15 min in the dark. The membrane was further washed by 8 M urea once and 200 mM TEAB three times. Trypsin (Promega) was added at 1:40 enzyme/substrate ratio. Devices were briefly centrifuged at 100g for 30 s and incubated overnight at 37 °C. Tryptic peptides were recovered by centrifu gation at 14,000g for 4 min. An additional 60 μ l of 200 mM TEAB, pH 8.5, was added to the devices and centrifuged as an additional elution step. This eluent was combined with the previous ones for further processing. Ten per cent of the eluents were dried in a SpeedVac and desalted with a C18 STAGE tip (Proxeon, Thermo Fisher) before being injected onto the mass spectrometer for LC-MS/MS acquisition. Deubiquitinase identification by mass spectrometry. Peptides were loaded onto an Acuity UPLC BEH130 C18 column (1.7 μ m, 12 Å, 100 μ m × 100 mm) at a flow rate of 1.5 μ l min −1 in solvent A (98% water/2% MeCN/0.1% formic acid) using a NanoAcquity UPLC system (Waters). Separation was achieved with a linear gradient of 2% solvent B (98% MeCN/2% water/0.1% formic acid) to 25% solvent B over 45 min. Eluted peptides were injected onto an Orbitrap Elite mass spectrometer (Thermo Fisher) using an Advance CaptiveSpray source (Bruker) at a voltage of 1.2 kV. Full MS scans were collected in the Orbitrap at 60,000 resolution, the top 15 most abundant ions were selected in a datadependent mode and frag mented with collisioninduced dissociation, and MS/MS were collected in the ion trap. MS/MS spectra were searched using Mascot (version 2.3.02) against a human proteome database (Uniprot, December 2011) with known contaminants along with all decoy sequences. Search parameters included trypsin cleavage allowing up to two missed cleavage events, a precursor ion tolerance of 50 p.p.m., and a fragment ion tolerance of 0.8 Da. Searches also allowed variable modifications of methionine oxidation (+ 15.9949 Da), and two cysteine modifications of either (+ 57.0215) for carbamidomethylation or (+ 192.0569 Da) for reacted DUB probe remnant. Peptide spectra matches were filtered with a false discovery rate of 5% on the peptide level and subsequently at 2% on the protein level. Each identified peptidespectrum match was quantified using areaundercurve, and the same quantification event was extended to other runs where such peptide was not identified by an MS/MS spectrum, based on exact precursor m/z and retentiontime matching. Statistical analysis of deubiquitinase activity data. Detected and quantified area undercurve measures from labelfree mass spectrometry were logarithmically (base 2) rescaled. Changes between inhibitor and controltreated lysate were compared by a linear mixedeffects model with fixed effects for treatments and random effects for peptide species and massspectrometry run. Computations were performed in R, version 3.3.0, using the R package lme4, with error degrees of freedom estimated by the Kenward-Roger method using the R package pbkrtest. For each protein, log 2 (fold change) in activity was normalized to that observed in a spikedin viral DUB or BSA control protein. Statistical significance of the observed 'inhibitorvscontrol' differences in log 2 (fold change) between each DUB and the control protein was then assessed by a tstatistic with Satterthwaiteestimated degrees of freedom, and corrected for multiplicity by the Benjamini-Hochberg false discovery rate method set at 0.10. Animal use and care. All animal work followed the recommendations of the Guide for Care and Use of Laboratory Animals with respect to restraint, husbandry, surgical procedures, feed and fluid regulation, and veterinary care. The animal care and use programme at Genentech is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International, which assures com pliance with accepted standards for the care and use of laboratory animals. Studies were tailored to minimize the number of animals used, yet allow sufficient numbers to address any variability in drug exposure or biomarker response. For efficacy studies where growth rate differences introduce some variability, n = 10 engrafted animals per treatment cohort followed recommended housing (five mice per cage) and provided sufficient statistical power for a wellbehaved xenograft model. For PD biomarker experiments, a lower number (n = 4) was sufficient to note a consistent response. Extra animals were engrafted to ensure sufficient animals had the desired range of tumour volumes at randomization, and cohorts were enrolled that had a balanced distribution of tumour volumes. Owing to the need to monitor potential adverse effects with first inlife assessment of novel compounds, no study was conducted under blinded conditions. DMPK analysis. In vitro DMPK studies were performed using standard protocols. GNE6776 was formulated as a suspension in 0.5% methylcellulose/0.2% Tween80 and was administered at 200 mg kg −1 (body weight) by oral gavage to female C.B-17 SCID mice, aged 12-16 weeks (Charles River Laboratories; n = 3 per time point). No randomization was used for DMPK studies. At 0.5, 1, 2, 4, 8 and 24 h postdose, blood samples were collected by terminal cardiac puncture into anticoagulant tubes (EDTA). Clarified plasma was then transferred to a fresh tube and snap frozen. GNE6776 plasma concentrations were determined by LC-MS/MS. In vivo pharmacodynamic response. For EOL1 AML xenograft studies, immu nodeficient C.B-17 SCID mice (Charles River Laboratories), aged 12-16 weeks, were inoculated subcutaneously on the right flank with five million cells in a 50:50 suspension of HBSS:Matrigel (BD Biosciences; 100 μ l). When tumour volumes reached between approximately 285 and 500 mm 3 , mice were distributed into volumematched cohorts (n = 4). For MCF7 breastcancer xenograft studies, immunodeficient nu/nu mice (Charles River Laboratories), aged 6-8 weeks, were implanted with 0.36 mg oestrogen pellets (Innovative Research of America) via trochar 1-3 days before tumour cell inoculation. Ten million MCF7Ser cells, an in vivooptimized MCF7 variant, were injected orthotopically into the 2/3 mammary fat pad of each mouse in a 50:50 suspension of HBSS:Matrigel (BD Biosciences) in a total volume of 100 μ l. When tumour volumes reached between approximately 285 and 450 mm 3 , mice were distributed into volumematched cohorts (n = 4). GNE6776 was formulated as a suspension in 0.5% methyl cellulose/0.2% Tween80 and administered at 200 mg kg −1 (body weight) by oral gavage at 0 and 4 h. 0.5% Methylcellulose/0.2% Tween80 control or GNE6776 treated samples were collected at 8 h after the first dose and excised tumours were flash frozen on dry ice. Tumours were lysed in RIPA buffer containing protease inhibitors (Roche) and 300 mM NaCl using a Qiagen TissueLyser. Samples were incubated on ice for 15 min and then centrifuged at 20,000g at 4 °C for 10 min. Protein levels in clarified lysates were quantified using a Pierce BCA assay kit and concentrations were normalized with sample buffer. Samples were run on gels, and proteins were transferred to membranes and western blotted as described above. In vivo efficacy study. For EOL1 AML xenograft studies, immunodeficient C.B-17 SCID mice (Charles River Laboratories), aged 12-16 weeks, were inoculated subcutaneously on the right flank with five million cells in a 50:50 suspension of HBSS:Matrigel (BD Biosciences; 100 μ l). When tumours became established (150-300 mm 3 ), mice were distributed into tumourvolumematched cohorts (n = 7, mean tumour volume ~ 250 mm 3 ). GNE6776 was formulated as a suspension in 0.5% methylcellulose/0.2% Tween80 and was administered at 100 or 200 mg kg −1 (body weight) by oral gavage on a once or twice daily schedule. Tumour volume measurements, body weight and body condition data were collected two or three times per week. The maximum tumour volume limit of 2,000 mm 3 was not reached in any animal. USP7 enzymatic analysis. Michaelis-Menten kinetic measurements with full length USP7 were performed using 1 nM USP7 with a series of ubiquitin-AMC substrate titrations. The initial rate of substrate hydrolysis was determined using the Magellan software on a Tecan Safire2 plate reader, and kinetic parameters modelled using nonlinear regression analysis with GraphPad Prism software. Standard error was calculated from three technical replicates. For studies using the USP7 D305/E308 mutant, samples were reacted in a buffer consisting of 50 mM HEPES (pH 7.5), 100 mM NaCl, 2.5 mM dithiothreitol, and 0.1% (w/v) bovine gamma globulin (Sigma catalogue number G500925G). The starting substrate concentration of ubiquitinRho110 (Boston Biochem catalogue number U555) used for the Michaelis-Menten analysis was 100 μ M serial diluted to 781 nM. Reactions were performed for 1 h at room temperature with a final enzyme con centration of 100 nM (three independent experiments, see symbols in plots), in black 100μ l volume 96well half area plates (Corning catalogue number 3993). The enzymatic activity was calculated by fitting the data using the initial velocity with the linear V 0 values measured by analysing the fluorescence signal of cleaved Rho110 using excitation at 485 nm and emission at 535 nm. X-ray crystallography. Crystals were grown by the hangingdrop method by mixing the USP7 catalytic domain (residues 208-554) at 15 mg ml −1 with an equal volume of reservoir solution containing 100 mM TrisHCl, pH 7.0, and 20% PEG1000 (v/v). Costructures with compounds were obtained by soaking crystals with 1 mM of compound overnight. Crystals were cryoprotected with reservoir solution supplemented with 20% glycerol (v/v) and flashfrozen in liquid nitrogen. Data collection and refinement statistics are detailed in Extended Data Fig. 8e . Generation of isotopically labelled di-ubiquitins. In both K48 and K63linked diubiquitin, the distal ubiquitin has isotopically labelled 15 NThr residues and the proximal ubiquitin has 15 NLeu residues. These are marked with asterisks in Fig. 4a .
The selectively labelled ubiquitin monomers were generated and purified as follows: ubiquitin was cloned into a PET3a vector and transformed into the auxotrophic strains RF2 and ML2 (a gift from R. Gennis and T. Iwasaki) and expressed with the following modifications. Bacterial cultures were grown at 37 °C in M9 medium supplemented with NH 4 Cl (2 g l −1
) and C 6 glucose (4 g l
−1
). Strain After reaching an absorbance of 0.6, the cells were induced with 1 mM IPTG and further grown for 6 h. Protein purification was performed at room temperature. Cells were collected and lysed in lysis buffer (50 mM HEPES 7.0). The cleared lysate was subjected to affinity chromatography using DEAE Sepharose Fast Flow (GE catalogue number 17070901). Ubiquitin was collected in the flow through and dialysed overnight into NaOAc, pH 4.5. Dialysed material was clarified by centrifugation at 35,000g and ubiquitin was subjected to ion exchange chromato graphy using a MonoS column (GE Healthcare, catalogue number 17516901). The following enzymes were obtained from Boston Biochem: UBE1 (catalogue number E305), UBE2K (catalogue number E2602) and UBE2N/UBE2V1 complex (catalogue number E2664).
K63 and K48linked diubiquitin chains were generated and purified as follows: in separate reactions incubating 250 nM E1 enzyme, 5 μ M UBE2K (K48 linked), or 5 μ M UBE2N/UBE2V1 complex (K63 linked) with equal molar ratios of 1 mM ubiquitin and 1 mM ubiquitin, 10 mM ATP, 50 mM HEPES (pH 8.0), 10 mM MgCl 2 in a 10 ml reaction at 37 °C. After 2 h, the reaction was acidified with 2 ml of 17.4 M glacial acetic acid. Obtained diubiquitins (K63 or K48linked) were purified by cation exchange using a MonoS column (GE Healthcare, catalogue number 17516901). All purified diubiquitin chains were buffer exchanged into 1× PBS buffer and proteins were flashfrozen in liquid nitrogen before storage at − 80 °C. Generation of 5-TAMRA-peptide/tetra-ubiquitin conjugates. K63 and K48 linked tetraubiquitin chains were obtained from Boston Biochem, K63linked (catalogue number UC310B), K48linked (catalogue number UC210B). The 5TAMRA (5carboxytetramethylrhodamine) peptide was generated by CPC Scientific consisting of the sequence 5TAMRAYPYDVPDYAIREIVSRNKRR YQEDG 19 . K63 or K48 tetraubiquitin chains were conjugated to the peptide as follows. (1) Generation of tetraubiquitinMESNA: incubating 250 nM E1, 10 mM MgCl 2 , 10 mM MgATP, 1 mM tetraubiquitin, and 100 mM MESNA (SigmaAldrich, catalogue number 63705), in 20 mM Na 2 HPO 4 at pH 8.0 at 37 °C overnight. This was then dialysed into 0.4% TFA, and tetraubiquitinMESNA was lyophilized. (2) Lyophilized tetraubiquitin was dissolved in DMSO at a concen tration of 0.5 mM and 2 mg of peptide added until all components were dissolved; reaction volume 1 ml. The reaction was initiated by adding NHS 27.5 mM (final concentration), AgNO 3 3.3 mM (final concentration), and 22 μ l DIPEA, and incu bated at room tempera ture overnight. The reaction was diluted ten times with doubledistilled H 2 O and desalted into PBS (pH 7.5). Nonconjugated peptide was removed by sizeexclusion chromatography. In a second step, nonconjugated tetraubiquitin was removed by ion exchange chromatography as described above and buffer exchanged into 1× PBS (pH 7.5). The concentration of the purified final conjugate was determined by absorbance using an extinction coefficient for 5TAMRA at 80,000 cm
TAMRA-peptide/tetra-ubiquitin conjugate depolymerization studies. For depolymerization assays, 100 nM USP7 (catalogue number E519, lot 09939314) or 100 nM USP7 catalytic domain Nterminal Histag (Genentech, Hs_USP7. K208K554) was diluted in 1× PBS buffer (pH 7.5) containing 5 mM DTT to generate 10× stock solutions in respect of the final concentration and preincubated at room temperature for 10 min. In a 90 μ l reaction, 9 μ g (2.7 μ M) of 5TAMRA peptide/tetraubiquitin (K63 or K48linked) was mixed with 9 μ l of diluted enzyme in 1× PBS buffer (pH 7.5). Aliquots of 10 μ l of the reaction were mixed with 4 μ l 2× SDS loading buffer at the time points indicated to stop the reaction. Samples (14 μ l) were subjected to SDS gelelectrophoresis using precast BioRad Criterion TGX 10-20% gels (catalogue number 5671114). Fluorescence was analysed using a FluorChem imager from Protein Simple according to the user's manual. Densitometry values were analysed using the software AlphaViewSA, ProteinSimple. Data and code availability. The 120 cell line exome dataset for Extended Data Fig. 5 and Supplementary Table 1 Supplementary Fig. 1 . e, Quantification of total and ubiquitinatedMDM2 (UbMDM2) in USP7 inhibitortreated cells. SJSA1 human osteosarcoma cells were treated with a range of concentrations of the indicated USP7 inhibitors or DMSO vehicle control for 24 h and the level of ubiquitinated MDM2 and total MDM2 were measured using a multiplexed mesoscale immunoassay. Graphs show experimental duplicates of the quantified level of either total MDM2 (right column, red), ubiquitinated MDM2 (central column, blue), or the percentage change in the ratio of the ubiquitinated MDM2 signal and the total MDM2 signal (left column, orange). All data are shown as percentage change in each value, relative to DMSO vehicle treated samples. The maximal extent of the increase in the ubiquitinated MDM2 to total MDM2 ratio varied between compounds; therefore to compare the potency of the increase in the ratio of ubiquitinatedMDM2 to total MDM2 between compounds, the top level was universally set to 100%. This normalization allowed calculation of the EC 50 of the percentage change in this ratio relative to DMSO (left column). Indole tricyclic compounds including GNE8735 increased total MDM2 levels and inhibited cathepsinB, indicating poor selectivity and induction of general cell stress by this chemical series (d, e) . Indole tricyclics also precipitated caspase3, although they passed dynamic light scattering analysis (see also Extended Data Fig. 2a ). The peptidomimetic compounds had weaker biochemical potency, poor selectivity, and covalently modified USP7 cysteine (Cys) residues other than the catalytic Cys (data not shown). Given these data, and because optimization of indole tricyclic and peptidomimetic compounds proved challenging, these series were discontinued. The tetrahydroacridine and fragment compounds were relatively potent, selective, and enhanced cellular MDM2 ubiquitination without significantly increasing total MDM2 (d, e). Tetrahydroacridine compounds passed cathepsinB inhibition assays, demonstrating additional protease selectivity. Neither tetrahydroacridine nor fragment compounds showed evidence of USP7 aggregation in dynamic light scattering or in NMR studies (data not shown; see Extended Data Fig. 2a ). Tetrahydroacridine compounds, including GNE6831, covalently modified USP7, consistent with a previous report describing a similar series 30 (see also Extended Data Fig. 2b ). 
Letter reSeArCH
Extended Data Figure 2 | Biophysical and cellular characterization of selected USP7 inhibitors. a, The dynamic light scattering autocorrelation functions are shown for 100 μ M rottlerin (red), fulllength USP7 with 100 μ M GNE8735 (blue), fulllength USP7 with 100 μ M GNE 2090 (brown), and fulllength USP7 with 0.1% DMSO vehicle control (black). The percentage aggregate by mass is shown in the legend. Two experimental replicates were performed. b, USP7 fulllength protein was incubated overnight with excess of GNE6831 and analysed by liquid chromatography-mass spectrometry. Unmodified and covalently modified USP7 are represented in the top and bottom panels, respectively. Three experimental replicates were performed. c, Table of active and inactive tetrahydroacridine compounds with structures. Hittolead selection assay data are listed in the indicated rows. Averages are shown ± s.e.m., where applicable, with the number of biologically independent experiments indicated below. n = 1 experimental replicate, if not specified. See Fig. 1b and text for more details. d, Table of active and inactive fragment compounds with structures. Hittolead selection assay data are listed in the indicated rows. Averages are shown ± s.e.m., where applicable, with the number of biologically independent experiments indicated below. n = 1 experimental replicate, if not specified. See Fig. 1b and text for more details. e, Cell viability assays in AMO1 cells treated as indicated with the tetrahydroacridine compounds (top graph: purple lines, inactive controls; green line, active compound) and fragment compounds (bottom graph: red lines, inactive controls; blue line, active compound). Experimental triplicate data normalized to vehicle control are plotted as a function of compound concentration. f, Cell viability assays in KMS12PE cells treated as indicated with the tetrahydroacridine compounds (top graph: purple line, inactive control; green lines, active compounds) and fragment compounds (bottom graph: red line, inactive control; blue line, active compound). Experimental triplicate data normalized to vehicle control are plotted as a function of compound concentration. Tetrahydroacridine compounds GNE6831 and GNE2090 decreased viability of KMS12PE and AMO1 multiple myeloma cell lines but this activity was not differentiated from control compounds GNE0956, GNE2143, and GNE2148. By contrast, the fragment compound GNE2916 decreased multiple myeloma cell viability significantly more than control compounds GNE2917, GNE2931, and GNE9603. Thus work on tetrahydroacridine series was discontinued and the fragment series was further optimized. Table summarizing deubiquitinase biochemical assay data and ubiquitin-MDM2 assay data from optimized fragment compounds and inactive controls. Averages are shown ± s.e.m, where applicable, with the number of biologically independent experiments indicated below. n = 1 experimental replicate, if not specified. Fragment compound structures are shown to the right. b, Representative western blot analysis of USP7, p53, and p21 levels from the cycloheximide (CHX)chase study of MDM2 turnover shown in Fig. 1c , performed in experimental triplicate. c. Analysis of endogenous MDM2 polyubiquitinated with K48linked chains. Top: denatured lysates from MCF7 cells treated for 8 h with the indicated compounds were immunoprecipitated with a K48 polyubiquitin linkagespecific antibody and immunocomplexes were western blotted with an antiMDM2 antibody. Western blot analysis of wholecell lysates for the indicated proteins are shown below. Representative of two experimental replicates. d, Cell viability of wildtype and USP7null HCT116 colon adenocarcinoma cells, treated as indicated, and analysed with a CellTiterGlo assay. Experimental triplicates normalized to vehicle control are plotted as a function of compound concentration. Top: averages ± s.e.m. Twosided ttests were used to calculate P values between wildtype HCT116 and USP7null cells treated with GNE6640: 7.5 μ M P = 0.01, 10 μ M P = 0.041, 12.5 μ M P = 0.009, 15 μ M P = 0.011, 20 μ M P = 0.017. Bottom: experimental triplicate data are shown. e. Cell viability of wildtype and USP7null HCT116 colon adenocarcinoma cells, treated and analysed as in d with the indicated doses of GNE6776. Top: averages are shown ± s.e.m. Twosided ttests were used to calculate P values between wildtype HCT116 and USP7null cells: 1 μ M P = 0.023, 2.5 μ M P = 0.003, 5 μ M P = 0.001, 7.5 μ M P = 0.003, 10 μ M P = 0.007, 12.5 μ M P = 0.001, 15 μ M P = 0.007, 17.5 μ M P = 0.001, 20 μ M P = 0.008. Bottom: experimental triplicate data are shown. Gel source data: Supplementary Fig. 1 . VCPIP  USP10  USP36  CYLD  USP16  USP20  USP28  USP47  USP9x  BAP1  USP25  USP8  USP21  Cezanne  TRABID  A20  OTUD5  AMSH  USP2  UCHL1  USP1  UCHL3  USP5  vOTU  BRCC3  OTUD1  USP4  OTUB2  UCHL5  USP27x  AMSH- 
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Extended Data Figure 8 | Enzymatic analysis and supporting structural biology data for USP7 inhibitors and USP7. a, Michaelis-Menten kinetic analysis of USP7 and a series of ubiquitinAMC substrate titrations with the indicated USP7 inhibitors. Initial rate of substrate hydrolysis was determined using the Magellan software on a Tecan Safire2 plate reader and kinetic parameters were modelled using nonlinear regression analysis with GraphPad Prism software. Averages with standard errors were calculated from three technical replicates and are representative of two (GNE6776) or three (GNE6640, GNE6641, and no inhibitor) biologically independent experiments. b, Affinity values of ubiquitin binding to USP7 catalytic domain in the absence and presence of USP7 inhibitors. The values were determined by titration of unlabelled ubiquitin to labelled USP7 catalytic domain and the NMR chemical shift changes were fitted as described in the Methods. The mean values and standard deviations are representative of three experimental replicates and were calculated by averaging the values obtained for eight independent chemical shift perturbations of the wellresolved cross peaks from Y339, S341, D342, G375, A381, G382, D412, and I419. c, Overlay of a region of the twodimensional 1 H/ 15 N TROSY spectrum of the USP7 catalytic domain (orange) highlighting changes induced by binding of ubiquitin in the absence (left, blue) and presence of GNE6640 (right, black). Individual peaks stemming from residues E371 and Q387 are highlighted. Data are representative of three experimental replicates. d, Comparison of the crystal structure of USP7 catalytic domain in complex with GNE 6640 (cyan) and GNE6776 (yellow). The catalytic domain is shown as an orange cartoon and the side chains of the residues in proximity to the inhibitor binding sites are shown as orange sticks. GNE6640 and GNE 6776 compound structures are indicated above. e, PDB accession numbers, data collection, and refinement statistics for GNE6640 and GNE6776 crystal structures with the USP7 catalytic domain. volumes at randomization, and cohorts are enrolled that have a balanced distribution of tumor volumes.
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